MAFLD predicts cardiovascular disease risk better than MASLD

Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic ca...

Full description

Saved in:
Bibliographic Details
Published inLiver international Vol. 44; no. 7; pp. 1567 - 1574
Main Authors Pan, Ziyan, Shiha, Gamal, Esmat, Gamal, Méndez‐Sánchez, Nahum, Eslam, Mohammed
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.07.2024
Subjects
Online AccessGet full text
ISSN1478-3223
1478-3231
1478-3231
DOI10.1111/liv.15931

Cover

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD). Methods Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed. Results MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone. Conclusions Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
AbstractList Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction-associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD). Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check-up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10-year ASCVD risk and self-reported cardiovascular events, were analysed. MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78-2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52-2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13-7.01; p < .03) than MASLD alone. Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction-associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).BACKGROUND AND AIMMetabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction-associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check-up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10-year ASCVD risk and self-reported cardiovascular events, were analysed.METHODSSix thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check-up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10-year ASCVD risk and self-reported cardiovascular events, were analysed.MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78-2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52-2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13-7.01; p < .03) than MASLD alone.RESULTSMAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78-2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52-2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13-7.01; p < .03) than MASLD alone.Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.CONCLUSIONSAlthough both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD). Methods Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed. Results MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone. Conclusions Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
Background and AimMetabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD).MethodsSix thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed.ResultsMAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p < .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p < .03) than MASLD alone.ConclusionsAlthough both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
Author Méndez‐Sánchez, Nahum
Eslam, Mohammed
Pan, Ziyan
Esmat, Gamal
Shiha, Gamal
Author_xml – sequence: 1
  givenname: Ziyan
  surname: Pan
  fullname: Pan, Ziyan
  organization: Westmead Hospital and University of Sydney
– sequence: 2
  givenname: Gamal
  orcidid: 0000-0002-9338-8854
  surname: Shiha
  fullname: Shiha, Gamal
  organization: Mansoura University
– sequence: 3
  givenname: Gamal
  surname: Esmat
  fullname: Esmat, Gamal
  organization: Cairo University
– sequence: 4
  givenname: Nahum
  orcidid: 0000-0001-5257-8048
  surname: Méndez‐Sánchez
  fullname: Méndez‐Sánchez, Nahum
  organization: Medica Sur Clinic Foundation
– sequence: 5
  givenname: Mohammed
  orcidid: 0000-0002-4315-4144
  surname: Eslam
  fullname: Eslam, Mohammed
  email: mohammed.eslam@sydney.edu.au
  organization: Westmead Hospital and University of Sydney
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38641962$$D View this record in MEDLINE/PubMed
BookMark eNp1kF1PwjAUhhuDkQ-98A-YJd7oxaBn3bot8YaAKMmIF37cNqXtYnFs2G4Y_r1FwAui5-acNM_7pnm6qFVWpULoEnAf3AwKve5DlBI4QR0I48QnAYHW7x2QNupau8AY0jSCM9QmCQ0hpUEH3c2Gk2zsrYySWtTWE9xIXa25FU3BjSe1Vdwqz2j74c1VXSvj1e-89GbD52x8jk5zXlh1sd899Dq5fxk9-tnTw3Q0zHxBIgK-wnSOAxA4oXGeU5njPKQR4ISDdFtCHKcRCbkKiaBA0zSGQCaxJHOcB8K99tDNrndlqs9G2ZottRWqKHipqsYygkOCYxqmW_T6CF1UjSnd7xxFE-cIU-qoqz3VzJdKspXRS2427ODFAYMdIExlrVE5E7rmta7K2nBdMMBsa5458-zHvEvcHiUOpX-x-_YvXajN_yDLpm-7xDczhI6T
CitedBy_id crossref_primary_10_1016_j_numecd_2025_104024
crossref_primary_10_1016_j_aohep_2024_101512
crossref_primary_10_1111_liv_70059
crossref_primary_10_1111_liv_15950
crossref_primary_10_1111_liv_15972
crossref_primary_10_20517_mtod_2024_39
crossref_primary_10_1111_liv_16099
crossref_primary_10_1111_liv_16096
crossref_primary_10_1007_s12072_024_10721_2
crossref_primary_10_1186_s12933_024_02434_5
crossref_primary_10_1016_j_aohep_2024_101573
crossref_primary_10_1186_s12876_025_03625_4
crossref_primary_10_1111_apt_18052
crossref_primary_10_1111_dom_16196
crossref_primary_10_1016_j_aohep_2024_101527
crossref_primary_10_1016_j_aohep_2024_101526
crossref_primary_10_1016_j_jhep_2024_08_005
crossref_primary_10_20517_mtod_2024_64
crossref_primary_10_20517_mtod_2024_143
crossref_primary_10_1111_liv_16000
crossref_primary_10_3389_fendo_2024_1494560
crossref_primary_10_1111_liv_16082
crossref_primary_10_1016_j_aohep_2024_101521
crossref_primary_10_1016_j_jhep_2024_12_019
crossref_primary_10_1007_s12072_024_10731_0
Cites_doi 10.1186/s12933-022-01697-0
10.1210/clinem/dgac321
10.3390/ijms222111629
10.1007/s12072-023-10543-8
10.1016/j.cgh.2020.04.083
10.1016/j.jhep.2020.03.039
10.1111/hepr.13685
10.1007/s12072-020-10094-2
10.1093/gastro/got007
10.1161/01.cir.0000437741.48606.98
10.1007/s12072-023-10620-y
10.1016/j.cgh.2020.12.022
10.1161/CIRCULATIONAHA.116.022367
10.1016/S2468-1253(21)00132-1
10.1038/s41575-022-00635-5
10.1016/S2468-1253(21)00183-7
10.1053/j.gastro.2019.11.312
10.1016/j.cgh.2018.04.043
10.1007/s10620-022-07508-6
ContentType Journal Article
Copyright 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
2024 John Wiley & Sons A/S
Copyright_xml – notice: 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
– notice: 2024 John Wiley & Sons A/S
DBID AAYXX
CITATION
NPM
7QO
7T5
7U9
8FD
FR3
H94
K9.
P64
RC3
7X8
DOI 10.1111/liv.15931
DatabaseName CrossRef
PubMed
Biotechnology Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Genetics Abstracts
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1478-3231
EndPage 1574
ExternalDocumentID 38641962
10_1111_liv_15931
LIV15931
Genre article
Journal Article
GrantInformation_xml – fundername: National Health and Medical Research Council of Australia (NHMRC) Program Grant
  funderid: APP1053206
– fundername: Project and ideas grants
  funderid: APP2001692; APP1107178; APP1108422
– fundername: National Health and Medical Research Council of Australia (NHMRC) Program Grant
  grantid: APP1053206
– fundername: Project and ideas grants
  grantid: APP1108422
– fundername: Project and ideas grants
  grantid: APP2001692
– fundername: Project and ideas grants
  grantid: APP1107178
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29L
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAKAS
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
ZXP
ZZTAW
~IA
~WT
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
NPM
7QO
7T5
7U9
8FD
FR3
H94
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3531-e06b021c0867ff6df0f465108a1d651d1779534ae43c61699712d87d3b0f2ce43
IEDL.DBID DR2
ISSN 1478-3223
1478-3231
IngestDate Tue Aug 05 11:13:14 EDT 2025
Wed Aug 13 07:20:46 EDT 2025
Thu Apr 03 07:04:56 EDT 2025
Tue Jul 01 04:10:11 EDT 2025
Thu Apr 24 22:59:01 EDT 2025
Wed Aug 20 07:26:49 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3531-e06b021c0867ff6df0f465108a1d651d1779534ae43c61699712d87d3b0f2ce43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9338-8854
0000-0001-5257-8048
0000-0002-4315-4144
PMID 38641962
PQID 3068931066
PQPubID 2045125
PageCount 8
ParticipantIDs proquest_miscellaneous_3043076494
proquest_journals_3068931066
pubmed_primary_38641962
crossref_citationtrail_10_1111_liv_15931
crossref_primary_10_1111_liv_15931
wiley_primary_10_1111_liv_15931_LIV15931
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2024
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: July 2024
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Liver international
PublicationTitleAlternate Liver Int
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2014; 129
2023; 21
2021; 6
2013; 1
2021; 22
2023; 17
2020; 73
2021; 19
2023; 101133
2019; 17
2022; 67
2016; 134
2020; 14
2022; 21
2020; 158
2022; 107
2021; 51
2024; 18
2022; 19
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
Feng G (e_1_2_10_4_1) 2023; 21
Rinella ME (e_1_2_10_11_1) 2023; 101133
e_1_2_10_2_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
References_xml – volume: 73
  start-page: 202
  issue: 1
  year: 2020
  end-page: 209
  article-title: A new definition for metabolic dysfunction‐associated fatty liver disease: an international expert consensus statement
  publication-title: J Hepatol
– volume: 6
  start-page: 864
  issue: 10
  year: 2021
  end-page: 873
  article-title: Defining paediatric metabolic (dysfunction)‐associated fatty liver disease: an international expert consensus statement
  publication-title: Lancet Gastroenterol Hepatol
– volume: 158
  start-page: 1999
  issue: 7
  year: 2020
  end-page: 2014.e1
  article-title: MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease
  publication-title: Gastroenterology
– volume: 134
  start-page: 1430
  issue: 19
  year: 2016
  end-page: 1440
  article-title: Predicting the 10‐year risks of atherosclerotic cardiovascular disease in Chinese population: the China‐PAR project (prediction for ASCVD risk in China)
  publication-title: Circulation
– volume: 19
  start-page: 2138
  issue: 10
  year: 2021
  end-page: 2147.e10
  article-title: Metabolic dysfunction‐associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study
  publication-title: Clin Gastroenterol Hepatol
– volume: 18
  start-page: 168
  issue: 1
  year: 2024
  end-page: 178
  article-title: Breaking new ground: MASLD vs. MAFLD‐which holds the key for risk stratification?
  publication-title: Hepatol Int
– volume: 17
  start-page: 773
  issue: 4
  year: 2023
  end-page: 791
  article-title: An international multidisciplinary consensus statement on MAFLD and the risk of CVD
  publication-title: Hepatol Int
– volume: 21
  start-page: 1
  year: 2023
  end-page: 11
  article-title: Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 22
  start-page: 11629
  issue: 21
  year: 2021
  article-title: Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases
  publication-title: Int J Mol Sci
– volume: 101133
  start-page: E93
  year: 2023
  end-page: E94
  article-title: A multi‐society Delphi consensus statement on new fatty liver disease nomenclature
  publication-title: Ann Hepatol
– volume: 14
  start-page: 889
  issue: 6
  year: 2020
  end-page: 919
  article-title: The Asian Pacific Association for the Study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
  publication-title: Hepatol Int
– volume: 21
  start-page: 270
  issue: 1
  year: 2022
  article-title: Metabolic dysfunction‐associated fatty liver disease and implications for cardiovascular risk and disease prevention
  publication-title: Cardiovasc Diabetol
– volume: 67
  start-page: 4919
  issue: 10
  year: 2022
  end-page: 4928
  article-title: MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check‐ups
  publication-title: Dig Dis Sci
– volume: 6
  start-page: 743
  issue: 9
  year: 2021
  end-page: 753
  article-title: Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
  publication-title: Lancet Gastroenterol Hepatol
– volume: 51
  start-page: 1115
  issue: 11
  year: 2021
  end-page: 1128
  article-title: MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach
  publication-title: Hepatol Res
– volume: 107
  start-page: 2691
  issue: 9
  year: 2022
  end-page: 2700
  article-title: Global prevalence and clinical characteristics of metabolic‐associated fatty liver disease: a meta‐analysis and systematic review of 10 739 607 individuals
  publication-title: J Clin Endocrinol Metab
– volume: 19
  start-page: 638
  issue: 10
  year: 2022
  end-page: 651
  article-title: Metabolic (dysfunction)‐associated fatty liver disease in individuals of normal weight
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 19
  start-page: 136
  issue: 1
  year: 2021
  end-page: 145.e6
  article-title: Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic Steatohepatitis–related, child–Pugh a cirrhosis
  publication-title: Clin Gastroenterol Hepatol
– volume: 129
  start-page: S49
  issue: 25_suppl_2
  year: 2014
  end-page: S73
  article-title: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines
  publication-title: Circulation
– volume: 17
  start-page: 156
  issue: 1
  year: 2019
  end-page: 163.e2
  article-title: Vibration‐controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
– volume: 1
  start-page: 19
  issue: 1
  year: 2013
  end-page: 26
  article-title: Update of liver fibrosis and steatosis with transient elastography (Fibroscan)
  publication-title: Gastroenterology Report
– volume: 21
  start-page: 1
  year: 2023
  ident: e_1_2_10_4_1
  article-title: Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
  publication-title: Nat Rev Gastroenterol Hepatol
– ident: e_1_2_10_7_1
  doi: 10.1186/s12933-022-01697-0
– ident: e_1_2_10_2_1
  doi: 10.1210/clinem/dgac321
– ident: e_1_2_10_6_1
  doi: 10.3390/ijms222111629
– ident: e_1_2_10_18_1
  doi: 10.1007/s12072-023-10543-8
– volume: 101133
  start-page: E93
  year: 2023
  ident: e_1_2_10_11_1
  article-title: A multi‐society Delphi consensus statement on new fatty liver disease nomenclature
  publication-title: Ann Hepatol
– ident: e_1_2_10_5_1
  doi: 10.1016/j.cgh.2020.04.083
– ident: e_1_2_10_8_1
  doi: 10.1016/j.jhep.2020.03.039
– ident: e_1_2_10_19_1
  doi: 10.1111/hepr.13685
– ident: e_1_2_10_16_1
  doi: 10.1007/s12072-020-10094-2
– ident: e_1_2_10_15_1
  doi: 10.1093/gastro/got007
– ident: e_1_2_10_12_1
  doi: 10.1161/01.cir.0000437741.48606.98
– ident: e_1_2_10_22_1
  doi: 10.1007/s12072-023-10620-y
– ident: e_1_2_10_21_1
  doi: 10.1016/j.cgh.2020.12.022
– ident: e_1_2_10_13_1
  doi: 10.1161/CIRCULATIONAHA.116.022367
– ident: e_1_2_10_17_1
  doi: 10.1016/S2468-1253(21)00132-1
– ident: e_1_2_10_3_1
  doi: 10.1038/s41575-022-00635-5
– ident: e_1_2_10_10_1
  doi: 10.1016/S2468-1253(21)00183-7
– ident: e_1_2_10_9_1
  doi: 10.1053/j.gastro.2019.11.312
– ident: e_1_2_10_14_1
  doi: 10.1016/j.cgh.2018.04.043
– ident: e_1_2_10_20_1
  doi: 10.1007/s10620-022-07508-6
SSID ssj0019951
Score 2.574557
Snippet Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of...
Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic...
Background and AimMetabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1567
SubjectTerms Arteriosclerosis
Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Fatty liver
Health risks
Liver
Liver diseases
Metabolism
Risk
Statistical analysis
Title MAFLD predicts cardiovascular disease risk better than MASLD
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.15931
https://www.ncbi.nlm.nih.gov/pubmed/38641962
https://www.proquest.com/docview/3068931066
https://www.proquest.com/docview/3043076494
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8QwFH6IB_HivoyOEkXES4e2ySQtehkcB5UZD254EEqTNiCOVWYR9Nf7ki44LiCeWtqELC8v733JWwD2qBZaxZ52ZOpKBCicObHm1EmDUMkAhayyWUt6F_z0hp3fNe-m4LD0hcnjQ1QHboYz7H5tGDyWw09M3n94baAstj7UHuUmbn77sgodZTyPLdhi5vofZWARVchY8VQ1J2XRNwVzUl-1AqczD_dlV3M7k8fGeCQb6v1LFMd_jmUB5gpFlLTylbMIU2m2BMutDEH40xvZJ9Y01J65L8FMr7iBX4ajXqvTbZOXgfkyGhI1Yc9KivseYizWibSuQsQczpNe66rbXoGbzsn18alTZGBwkETUc1KXS1QCFOIeoTVPtKtN7nQ3iL0En4knRNikLE4ZVdzjYSg8PwlEQqWrfYVfV2E6e87SdSBUxIjVONYUnLmxjzgmNGAGNToqkqaswUFJi0gV4clNlox-VMIUnKTITlINdquiL3lMjp8K1UuCRgVbDiPER6ifIQrmNdipfiNDmVuSOEufx6YMw32Ps5DVYC1fCFUrNOAMB-FjZy05f28-6p7d2peNvxfdhFkfVabcGLgO06PBON1ClWckt-3a_gAhiPf8
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD6qQBq8jI0C62DgTdPES6okdu1E4qUaVAWaPnBTX6YodmIJ0aVVL5PGr9-xc9HKQJp4SuLY8vX4fJ99fAzwlWqhVeJpR2auRILCmZNoTp0sCJUMUMkqe2tJNOT9W3Yx6owacFKdhSn8Q9QLbkYy7HxtBNwsSP8l5eP7X21UxuYQ9brdnzOQ6Kp2HmXOHlu6xYwBAGrB0q-QseOpk65qo38g5ipitSqntwU_qsIWliYP7eVCttXjEz-Or63NO3hbYlHSLQbPe2hk-TY0uzny8J-_yTdirUPtsvs2vInKTfgmnETd3uCUTGcmZDEnasWklZRbPsQYrRNpTwsRsz5Pou714HQHbntnN9_7TnkJg4O9RD0nc7lEHKCQ-giteapdba5Pd4PES_GZekKEHcqSjFHFPR6GwvPTQKRUutpXGLoLa_kkzz4AoSJBusYxpeDMTXykMqHhMwjqqEg7sgXHVWfEqvRQbi7KGMcVU8FGim0jteBLHXVauOV4LtJB1aNxKZnzGCkSQjQkwrwFn-vfKFNmoyTJs8nSxGE49XEWshbsFSOhzoUGnGElfCys7c-Xs48H53f25eP_Rz2Cjf5NNMDv4eU-bPqIoArb4ANYW8yW2SdEQAt5aAf6H7Qg_Bo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED9CBqEv69Z0rbeu00Ype3GwLUWyaV9Cs5BuSSjtMvJQMJZsQVnnhDQZrH99T_IHy7pB2ZNtWUKfp_v9pNMJ4IhqoVXia1dmnkSCwpmbaE7dLIyUDFHJKntryXjCh1P2edadNeCkOgtT-IeoF9yMZNj52gj4ItW_Cfntzc8O6mJzhvoZ46gmDSK6rH1HmaPHlm0xs_-PSrB0K2TMeOqkm8roEcLcBKxW4wy24boqa2Fo8r2zXsmOuv_DjeN_VuYFPC-RKOkVQ-clNLJ8B9q9HFn4j1_kmFjbULvovgOtcbkF34bTcW8w6pPF0oSs7ojaMGgl5YYPMSbrRNqzQsSszpNx72rU34Xp4NPXs6FbXsHgYh9R3808LhEFKCQ-Qmueak-by9O9MPFTfKa-EFGXsiRjVHGfR5HwgzQUKZWeDhSGvoJmPs-zfSBUJEjWOKYUnHlJgEQmMmwGIR0VaVc68LHqi1iV_snNNRm3ccVTsJFi20gOfKijLgqnHH-LdFB1aFzK5V2MBAkBGtJg7sD7-jdKlNkmSfJsvjZxGE58nEXMgb1iINS50JAzrESAhbXd-e_s49H5N_vy-ulR30Hroj_Az8mXN7AVIHwqDIMPoLlarrO3CH9W8tAO8we7LfrJ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MAFLD+predicts+cardiovascular+disease+risk+better+than+MASLD&rft.jtitle=Liver+international&rft.au=Pan%2C+Ziyan&rft.au=Shiha%2C+Gamal&rft.au=Esmat%2C+Gamal&rft.au=M%C3%A9ndez-S%C3%A1nchez%2C+Nahum&rft.date=2024-07-01&rft.eissn=1478-3231&rft_id=info:doi/10.1111%2Fliv.15931&rft_id=info%3Apmid%2F38641962&rft.externalDocID=38641962
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon